Patients with peripherally located tumors will receive 48 cobalt gray equivalent over 2 weeks; patients with centrally located lung tumors will receive 60 cobalt gray equivalent over 2 to 3 weeks.

The primary outcome is grade 3 or higher toxicity; secondary outcomes include outcomes, survival, and quality of life.

Continue Reading

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit

Status: This study is open and recruiting patients as of April 14, 2017.

This study is sponsored by the University of Florida.


  1. Proton therapy for stage I non-small cell lung cancer (LU03) (LU03). NCT00875901. Accessed April 14, 2017.